Phosphaturic mesenchymal tumors: what an endocrinologist should know

J. M. Boland, Peter Tebben, A. L. Folpe

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Tumor-induced osteomalacia (TIO), also known as “oncogenic osteomalacia”, is a rare cause of osteomalacia. TIO often has an insidious onset characterized clinically by progressive muscle weakness and bone pain with fractures. The hallmark biochemical finding is a persistent low serum phosphorus concentration due to renal phosphate wasting. The vast majority of cases of TIO result from production of the phosphaturic hormone fibroblast growth factor 23 (FGF23) by a histologically distinctive mesenchymal tumor, termed “phosphaturic mesenchymal tumor” (PMT). Circulating FGF23 induces internalization of renal sodium/phosphate co-transporters resulting in reduced proximal tubular phosphate reabsorption. FGF23 also inhibits production of 1α,25-dihydroxyvitamin D which is inappropriately low or normal in the context of hypophosphatemia. Diagnosis is often delayed owing to the rarity of the condition and an underappreciation for the role of phosphorus as a cause for the constellation of symptoms. Primary treatment for TIO is identification of the offending tumor and surgical removal. However, these tumors are notoriously difficult to find, precluding the opportunity for a curative surgery in many. In such cases, phosphate and calcitriol therapy is used to improve symptoms and heal the osteomalacia. Recently, molecular genetic studies have shown recurrent genetic events in PMT, including the novel fusions FN1–FGFR1 and less commonly FN1–FGF1. These fusion events are hypothesized to result in autocrine/paracrine signaling loops within the tumor, spurring tumorigenesis. This review will cover the clinical features, imaging characteristics, pathologic features, molecular genetic aspects, and therapy of PMT, with a brief discussion of other neoplasms that may cause TIO.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalJournal of Endocrinological Investigation
DOIs
StateAccepted/In press - Feb 14 2018

Fingerprint

Neoplasms
Osteomalacia
Phosphates
Phosphorus
Molecular Biology
Sodium-Phosphate Cotransporter Proteins
Autocrine Communication
Paracrine Communication
Hypophosphatemia
Symporters
Kidney
Endocrinologists
Calcitriol
Muscle Weakness
Genetic Therapy
Oncogenic osteomalacia
Carcinogenesis
Hormones
Bone and Bones
Pain

Keywords

  • Hyperphosphaturia
  • Hypophosphatemia
  • Phosphaturic mesenchymal tumor
  • Rickets
  • Tumor-induced osteomalacia

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Phosphaturic mesenchymal tumors : what an endocrinologist should know. / Boland, J. M.; Tebben, Peter; Folpe, A. L.

In: Journal of Endocrinological Investigation, 14.02.2018, p. 1-12.

Research output: Contribution to journalArticle

@article{1ac7d70326e44559b403952b47f75226,
title = "Phosphaturic mesenchymal tumors: what an endocrinologist should know",
abstract = "Tumor-induced osteomalacia (TIO), also known as “oncogenic osteomalacia”, is a rare cause of osteomalacia. TIO often has an insidious onset characterized clinically by progressive muscle weakness and bone pain with fractures. The hallmark biochemical finding is a persistent low serum phosphorus concentration due to renal phosphate wasting. The vast majority of cases of TIO result from production of the phosphaturic hormone fibroblast growth factor 23 (FGF23) by a histologically distinctive mesenchymal tumor, termed “phosphaturic mesenchymal tumor” (PMT). Circulating FGF23 induces internalization of renal sodium/phosphate co-transporters resulting in reduced proximal tubular phosphate reabsorption. FGF23 also inhibits production of 1α,25-dihydroxyvitamin D which is inappropriately low or normal in the context of hypophosphatemia. Diagnosis is often delayed owing to the rarity of the condition and an underappreciation for the role of phosphorus as a cause for the constellation of symptoms. Primary treatment for TIO is identification of the offending tumor and surgical removal. However, these tumors are notoriously difficult to find, precluding the opportunity for a curative surgery in many. In such cases, phosphate and calcitriol therapy is used to improve symptoms and heal the osteomalacia. Recently, molecular genetic studies have shown recurrent genetic events in PMT, including the novel fusions FN1–FGFR1 and less commonly FN1–FGF1. These fusion events are hypothesized to result in autocrine/paracrine signaling loops within the tumor, spurring tumorigenesis. This review will cover the clinical features, imaging characteristics, pathologic features, molecular genetic aspects, and therapy of PMT, with a brief discussion of other neoplasms that may cause TIO.",
keywords = "Hyperphosphaturia, Hypophosphatemia, Phosphaturic mesenchymal tumor, Rickets, Tumor-induced osteomalacia",
author = "Boland, {J. M.} and Peter Tebben and Folpe, {A. L.}",
year = "2018",
month = "2",
day = "14",
doi = "10.1007/s40618-018-0849-5",
language = "English (US)",
pages = "1--12",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",

}

TY - JOUR

T1 - Phosphaturic mesenchymal tumors

T2 - what an endocrinologist should know

AU - Boland, J. M.

AU - Tebben, Peter

AU - Folpe, A. L.

PY - 2018/2/14

Y1 - 2018/2/14

N2 - Tumor-induced osteomalacia (TIO), also known as “oncogenic osteomalacia”, is a rare cause of osteomalacia. TIO often has an insidious onset characterized clinically by progressive muscle weakness and bone pain with fractures. The hallmark biochemical finding is a persistent low serum phosphorus concentration due to renal phosphate wasting. The vast majority of cases of TIO result from production of the phosphaturic hormone fibroblast growth factor 23 (FGF23) by a histologically distinctive mesenchymal tumor, termed “phosphaturic mesenchymal tumor” (PMT). Circulating FGF23 induces internalization of renal sodium/phosphate co-transporters resulting in reduced proximal tubular phosphate reabsorption. FGF23 also inhibits production of 1α,25-dihydroxyvitamin D which is inappropriately low or normal in the context of hypophosphatemia. Diagnosis is often delayed owing to the rarity of the condition and an underappreciation for the role of phosphorus as a cause for the constellation of symptoms. Primary treatment for TIO is identification of the offending tumor and surgical removal. However, these tumors are notoriously difficult to find, precluding the opportunity for a curative surgery in many. In such cases, phosphate and calcitriol therapy is used to improve symptoms and heal the osteomalacia. Recently, molecular genetic studies have shown recurrent genetic events in PMT, including the novel fusions FN1–FGFR1 and less commonly FN1–FGF1. These fusion events are hypothesized to result in autocrine/paracrine signaling loops within the tumor, spurring tumorigenesis. This review will cover the clinical features, imaging characteristics, pathologic features, molecular genetic aspects, and therapy of PMT, with a brief discussion of other neoplasms that may cause TIO.

AB - Tumor-induced osteomalacia (TIO), also known as “oncogenic osteomalacia”, is a rare cause of osteomalacia. TIO often has an insidious onset characterized clinically by progressive muscle weakness and bone pain with fractures. The hallmark biochemical finding is a persistent low serum phosphorus concentration due to renal phosphate wasting. The vast majority of cases of TIO result from production of the phosphaturic hormone fibroblast growth factor 23 (FGF23) by a histologically distinctive mesenchymal tumor, termed “phosphaturic mesenchymal tumor” (PMT). Circulating FGF23 induces internalization of renal sodium/phosphate co-transporters resulting in reduced proximal tubular phosphate reabsorption. FGF23 also inhibits production of 1α,25-dihydroxyvitamin D which is inappropriately low or normal in the context of hypophosphatemia. Diagnosis is often delayed owing to the rarity of the condition and an underappreciation for the role of phosphorus as a cause for the constellation of symptoms. Primary treatment for TIO is identification of the offending tumor and surgical removal. However, these tumors are notoriously difficult to find, precluding the opportunity for a curative surgery in many. In such cases, phosphate and calcitriol therapy is used to improve symptoms and heal the osteomalacia. Recently, molecular genetic studies have shown recurrent genetic events in PMT, including the novel fusions FN1–FGFR1 and less commonly FN1–FGF1. These fusion events are hypothesized to result in autocrine/paracrine signaling loops within the tumor, spurring tumorigenesis. This review will cover the clinical features, imaging characteristics, pathologic features, molecular genetic aspects, and therapy of PMT, with a brief discussion of other neoplasms that may cause TIO.

KW - Hyperphosphaturia

KW - Hypophosphatemia

KW - Phosphaturic mesenchymal tumor

KW - Rickets

KW - Tumor-induced osteomalacia

UR - http://www.scopus.com/inward/record.url?scp=85042140619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042140619&partnerID=8YFLogxK

U2 - 10.1007/s40618-018-0849-5

DO - 10.1007/s40618-018-0849-5

M3 - Article

C2 - 29446010

AN - SCOPUS:85042140619

SP - 1

EP - 12

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

ER -